Costs and consequences of cardiovascular toxicity due to Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia
The clinical and economic burden of cardiovascular toxicity associated with BTKis treatment among CLL patients is high, with ibrutinib showing the highest impact in comparison to the more selective BTKis.
Authors
- Pedro Gonçalves-Teixeira
- Débora Figueira
- Margarida Borges
- Mariana Paiva
- Andreia Magalhães
- João Costa
- Mariana Saraiva
- Manuela Fiuza
Institutions
- University of Lisbon (PT)
- IQVIA (United Kingdom) (GB)
- Administração Regional de Saúde de Lisboa e Vale do Tejo (PT)
- Centro Hospitalar de Vila Nova de Gaia (PT)
- Hospital de Santa Maria (PT)
Publication Details
- Journal
- Revista Portuguesa de Cardiologia
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1016/j.repc.2025.11.007
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00